City

Boston (1)

Shanghai (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Sign in for free

Phase

n/a (1)

phase 1/phase 2 (1)

Sponsor

Guy's and St Thomas' NHS Foundation Trust (1)

Massachusetts General Hospital (1)

RenJi Hospital (1)

Collaborator

Array BioPharma (1)

King's College London (1)

Pfizer (1)

Intervention

18f-fspg pet/ct in hnscc (1)

18f-fspg pet/ct in nsclc (1)

binimetinib (1)

crizotinib (1)

lenvatinib oral product plus vic1911 (1)

lorlatinib (1)

tno155 (1)

Study Documents

Intervention Type

drug (2)

diagnostic test (1)

Funder Type

Other (3)

Study Type

Interventional (2)

Observational (1)

resistant cancer

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Therapy Using 18F-FSPG PET

Not yet recruiting

Cancer
+3 more

18F-FSPG PET/CT in NSCLC
18F-FSPG PET/CT in HNSCC

(no location specified)

May 24, 2023

Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)

Not yet recruiting

Liver Cancer
+2 more

Lenvatinib Oral Product Plus VIC1911

Shanghai, China

Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine,

Jan 30, 2023

Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

Recruiting

Lung Cancer
+6 more

Lorlatinib
+3 more

Boston, Massachusetts
+1 more

Mar 7, 2021